Drug companies could face new penalties for settlement deals that delay cheaper generic or biosimilar drugs. The FTC could sue, and some first generic companies could lose their 180-day exclusivity if they violate the rule.
Modern Action explains what the legislation does, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.
Preserve Access to Affordable Generics and Biosimilars Act is a Senate bill waiting for floor action. The latest recorded action: Placed on Senate Legislative Calendar under General Orders. Calendar No. 46.
Latest action on S. 1096: Placed on Senate Legislative Calendar under General Orders. Calendar No. 46.
Who this affects: This bill mainly affects brand-name drug makers, generic drug companies, and biosimilar companies because it changes what they can agree to when settling patent fights. It also affects the FTC and the Department of Justice, which would get more filings and more enforcement power. Patients, insurers, and government health programs could be affected if the bill changes how fast lower-cost drugs reach the market.
Why this matters: This bill matters because delayed generic and biosimilar competition can keep drug prices higher for longer. The bill tries to stop settlement deals that may slow down cheaper alternatives. That could help some patients, insurers, and public programs pay less for medicine if more lower-cost products reach the market sooner. At the same time, the bill raises the legal risk of settling patent disputes, so it could change how drug companies fight, settle, and structure these agreements.
You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.
Officially: Preserve Access to Affordable Generics and Biosimilars Act
Drug companies could face new penalties for settlement deals that delay cheaper generic or biosimilar drugs. The FTC could sue, and some first generic companies could lose their 180-day exclusivity if they violate the rule.
Use this page to support, oppose, or ask Congress to amend S.1096. Modern Action explains what the bill does, helps identify the right senators or representative, and drafts a bill-specific message you can edit and send.
Where it stands
floor_pending
Your representatives are deciding where they stand. A few messages can tip the balance.
↓ Why your message matters here
This bill is moving through Congress right now — your representative needs to hear from you.
Enter your ZIP to see how your senators and member of Congress have voted, sponsored, or spoken on this bill.
Where this bill is in the process
Introduced
Introduced in Senate
Senate Committee
Under Senate committee consideration
Senate Floor Vote
Voted on by Senate
Latest: Placed on Senate Legislative Calendar under General Orders. Calendar No. 46. (4/10/2025)
Passed Senate
Approved by Senate
House Review
Sent to House for consideration
Passed Both Chambers
Approved by both House and Senate
Signed into Law
Signed by the President
For more detail
Choose one clear position: support, oppose, or amend. Then pick any reasons or personal context you want included. Modern Action uses that input and the bill context to draft a message you can edit and send.
Congressional offices prioritize messages from their own constituents. Modern Action uses your address to route the drafted message to your senators when that is the most relevant target for this bill.
The draft includes the bill number, your position, the reasons you selected, any personal context you added, and a direct ask such as voting yes, voting no, cosponsoring, opposing, or seeking changes. You stay in control because you can edit the message before sending.
This page gives you an opportunity to support, oppose, or ask for changes to Preserve Access to Affordable Generics and Biosimilars Act, then contact the elected officials who can act. Modern Action drafts the message from your position and the reasons you select.
Modern Action keeps the action tied to the bill itself: what it does, where it is in the process (floor pending), which office can still act, and what ask belongs in the message.
You are not starting from a blank form. Modern Action drafts the message around S.1096, your stance, and the reasons you choose, then lets you edit and send when ready.
